



Press release

Stockholm, 21 February 2017

New clinical study from Hong Kong confirms reduced infections for long-term users

A recent, independent clinical study conducted in Hong Kong confirms that Bactiguard-coated Foley catheters reduce symptomatic catheter associated urinary tract infections and that the effect is even more pronounced among long-term users.

"Given our recent market entry into China and Hong Kong we are pleased that the study confirms previously published results. It is also very encouraging that it shows more pronounced benefits for long-term users, who may be chronically dependent on catheterization," says Johan Rugfelt, COO.

This is the first study conducted in a Chinese population and included 306 patients from a rehabilitation hospital in Hong Kong. The incidence of catheter associated urinary tract infections was 31% lower for patients with Bactiguard-coated Foley catheters (BIP Foley) compared to patients with standard latex Foley catheters ($P=0.095$). A subgroup analysis showed a 48% lower infection rate among long-term users (~60 days with catheter) with Bactiguard coated catheters compared to standard catheters ($P=0.027$). The study is published in the Hong Kong Medical Journal.*.

* The study is now available on the Hong Kong Medical Journal webpage (and will be soon available at PubMed):

<http://www.hkmj.org/earlyrelease/hkmj164906.htm>

For further information, please contact:

Johan Rugfelt, COO, mobile: +46 708 72 47 39

About Bactiguard

Bactiguard is a Swedish medtech company with a global presence, offering a solution that prevents healthcare associated infections caused by medical devices. By preventing infections, we contribute to a reduced use of antibiotics and the spread of multi-resistant bacteria, which is a growing problem worldwide. We save lives, increase patient safety and significantly reduce the cost for the healthcare and society. Our technology is well-proven, safe and tissue friendly and consist of a thin layer of noble metals that prevents bacterial growth. The coating can be applied on almost all medical devices. Bactiguard-coated urinary catheters are market leading in the US and Japan and the company has also its own product portfolio consisting of Foley catheters, central venous catheters and endotracheal tubes. Bactiguard is a growth company, focused on markets in Europe, Middle East, Asia and Latin America. The company has about 60 employees worldwide, mainly at the headquarters in Stockholm and the production facility in Malaysia and is listed on Nasdaq Stockholm. Read more about Bactiguard at www.bactiguard.com